HLS Therapeutics Inc Stock Toronto S.E.
Stocks
AM
CA05328X1015
Pharmaceuticals
OTC Markets Traded| Market Cap | 90.43M 78.22M 73.05M 67.01M 126M 8.61B 128M 857M 336M 4.31B 340M 332M 14.26B | P/E 2026 * |
-14.5x | P/E 2027 * | -96.4x |
|---|---|---|---|---|---|
| Enterprise Value | 90.43M 78.22M 73.05M 67.01M 126M 8.61B 128M 857M 336M 4.31B 340M 332M 14.26B | EV / Sales 2026 * |
1.56x | EV / Sales 2027 * | 1.41x |
| Free-Float |
99.47% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HLS Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 58 | 01/05/2023 |
John Hanna
DFI | Director of Finance/CFO | 61 | 26/01/2024 |
Jason Gross
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/06/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Rodney Hill
BRD | Director/Board Member | 58 | 12/03/2018 |
John Welborn
CHM | Chairman | 48 | 22/06/2023 |
Norma Beauchamp
BRD | Director/Board Member | 65 | 01/01/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.41% | - | - | 90.43M | |
| +2.39% | +7.94% | +32.71% | +105.73% | 101B | |
| +0.43% | +0.86% | +50.72% | +157.34% | 55.37B | |
| -0.67% | +0.68% | +3.50% | +274.68% | 24.21B | |
| +1.64% | -0.95% | -12.47% | -14.01% | 8.29B | |
| +2.21% | +1.79% | -30.23% | -26.46% | 7.53B | |
| +0.59% | -1.84% | -9.64% | -21.74% | 6.75B | |
| +0.22% | +3.42% | +19.47% | +15.38% | 6.19B | |
| 0.00% | -2.78% | -4.03% | +21.42% | 5.07B | |
| +0.81% | -3.11% | -6.73% | -7.85% | 3.69B | |
| Average | +0.77% | -0.07% | +4.81% | +56.05% | 24.28B | |
| Weighted average by Cap. | +1.35% | +1.47% | +26.95% | +118.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 58.03M 50.2M 46.88M 43M 80.88M 5.52B 82.16M 550M 216M 2.77B 218M 213M 9.15B | 64.31M 55.63M 51.95M 47.66M 89.64M 6.12B 91.06M 610M 239M 3.07B 242M 236M 10.14B |
| Net income | -6.26M -5.42M -5.06M -4.64M -8.73M -596M -8.87M -59.37M -23.3M -299M -23.52M -23.01M -988M | -1.05M -908K -848K -778K -1.46M -99.93M -1.49M -9.95M -3.91M -50.09M -3.94M -3.86M -166M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
